Adora1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
ADORA1 (Adenosine A1 Receptor) encodes the adenosine A1 receptor, a Gi/o protein-coupled receptor that inhibits adenylate cyclase and reduces intracellular cAMP levels. The ADORA1 gene is located on chromosome 1q32.1 and encodes a 326-amino acid protein that is widely expressed throughout the central and peripheral nervous systems. The A1 receptor is the most abundant adenosine receptor in the brain and plays crucial roles in regulating neuronal excitability, neurotransmitter release, sleep, and protective responses to metabolic stress. Dysregulation of ADORA1 signaling is implicated in epilepsy, pain disorders, sleep disturbances, and neurodegenerative diseases including Alzheimer's disease.
The ADORA1 gene consists of multiple exons spanning approximately 20 kb:
| Region | Function |
|---|---|
| 5' UTR | Contains upstream open reading frames (uORFs) that regulate translation |
| Coding sequence | Seven transmembrane domains |
| 3' UTR | Contains miRNA binding sites |
The adenosine A1 receptor follows the canonical GPCR architecture:
Upon adenosine binding, A1 receptor activates Gi/o proteins:
Adenosine → A1R → Gi/o activation
↓
┌─────────┴─────────┐
↓ ↓ ↓
Adenylyl GIRK Ca²⁺
cyclase channels channels
(inhibit) (activate)(inhibit)
↓ ↓ ↓
cAMP↓ Hyperpolarization Ca²⁺↓
Primary signaling mechanisms:
ADORA1 has the broadest distribution of all adenosine receptors:
| Tissue | Expression Level | Primary Function |
|---|---|---|
| Brain (cortex) | Very High | Neuronal inhibition |
| Brain (hippocampus) | High | Memory modulation |
| Brain (spinal cord) | High | Pain processing |
| Heart | High | Cardioprotection |
| Kidney | High | Renal function |
| Adipose tissue | Moderate | Lipid metabolism |
| Immune cells | Variable | Immunomodulation |
A1 receptors are the brain's primary inhibitory adenosine receptors:
A1 receptor activation provides protection through:
Adenosine accumulates during wakefulness:
A1 receptors play complex roles in seizure regulation:
A1 receptors are key mediators of adenosine analgesia:
A1 receptor changes in AD:
| Drug | Mechanism | Status |
|---|---|---|
| Adenosine | A1 agonist | FDA approved (SVT) |
| Regadenoson | A2a agonist | FDA approved (stress test) |
| Rolofylline | A1 antagonist | Phase III (heart failure) |
| CVT-510 | A1 agonist | Clinical trials |
The study of Adora1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1]: https://pubmed.ncbi.nlm.nih.gov/10629201/ PMID:10629201
[2]: https://pubmed.ncbi.nlm.nih.gov/10816402/ PMID:10816402
[3]: https://pubmed.ncbi.nlm.nih.gov/15604288/ PMID:15604288
[4]: https://pubmed.ncbi.nlm.nih.gov/17585956/ PMID:17585956
[5]: https://pubmed.ncbi.nlm.nih.gov/19029120/ PMID:19029120
[6]: https://pubmed.ncbi.nlm.nih.gov/21885568/ PMID:21885568
[7]: https://pubmed.ncbi.nlm.nih.gov/22949693/ PMID:22949693
[8]: https://pubmed.ncbi.nlm.nih.gov/25666150/ PMID:25666150